CoChat

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease

Open access
Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B. · 2014 · Brain
Cited by 118

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Impulsivity is common in Parkinson's disease even in the absence of impulse control disorders. It is likely to be multifactorial, including a dopaminergic 'overdose' and structural changes in the frontostriatal circuits for motor control. In addition, we proposed that changes in serotonergic projections to the forebrain also contribute to response inhibition in Parkinson's disease, based on preclinical animal and human studies. We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves response inhibition, in terms of both behaviour and the efficiency of underlying neural mechanisms. This multimodal magnetic resonance imaging study used a double-blind randomized placebo-controlled crossover design with an integrated Stop-Signal and NoGo paradigm. Twenty-one patients with idiopathic Parkinson's disease (46-76 years old, 11 male, Hoehn and Yahr stage 1.5-3) received 30 mg citalopram or placebo in addition to their usual dopaminergic medication in two separate sessions. Twenty matched healthy control subjects (54-74 years old, 12 male) were tested without medication. The effects of disease and drug on behavioural performance and regional brain activity were analysed using general linear models. In addition, anatomical connectivity was examined using diffusion tensor imaging and tract-based spatial statistics. We confirmed that Parkinson's disease caused impairment in response inhibition, with longer Stop-Signal Reaction Time and more NoGo errors under placebo compared with controls, without affecting Go reaction times. This was associated with less stop-specific activation in the right inferior frontal cortex, but no significant difference in NoGo-related activation. Although there was no beneficial main effect of citalopram, it reduced Stop-Signal Reaction Time and NoGo errors, and enhanced inferior frontal activation, in patients with relatively more severe disease (higher Unified Parkinson's Disease Rating Scale motor score). The behavioural effect correlated with the citalopram-induced enhancement of prefrontal activation and the strength of preserved structural connectivity between the frontal and striatal regions. In conclusion, the behavioural effect of citalopram on response inhibition depends on individual differences in prefrontal cortical activation and frontostriatal connectivity. The correlation between disease severity and the effect of citalopram on response inhibition may be due to the progressive loss of forebrain serotonergic projections. These results contribute to a broader understanding of the critical roles of serotonin in regulating cognitive and behavioural control, as well as new strategies for patient stratification in clinical trials of serotonergic treatments in Parkinson's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awu032

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Agnoli, 2012, Dorsal-striatal 5-HT2A and 5-HT2C receptors control impulsivity and perseverative responding in the 5-choice serial reaction time task, Psychopharmacology (Berl), 219, 633, 10.1007/s00213-011-2581-0 · DOI
  2. Albizu, 2011, Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors, Neuropharmacology, 61, 770, 10.1016/j.neuropharm.2011.05.023 · DOI · Paper page
  3. Anderson, 2002, 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI, Neuroreport, 13, 1547, 10.1097/00001756-200208270-00012 · DOI · Paper page
  4. Baarendse, 2012, Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats, Psychopharmacology (Berl), 219, 13, 10.1007/s00213-011-2576-x · DOI · Paper page
  5. Badre, 2007, Left ventrolateral prefrontal cortex and the cognitive control of memory, Neuropsychologia, 45, 2883, 10.1016/j.neuropsychologia.2007.06.015 · DOI · Paper page
  6. Bari, 2009, Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats, Psychopharmacology (Berl), 205, 273, 10.1007/s00213-009-1537-0 · DOI · Paper page
  7. Bentivoqlio, 2012, Neuropsychological features of patients with Parkinson's disease and impulse control disorders, Neuro Sci, 34, 1207, 10.1007/s10072-012-1224-5 · DOI
  8. Borroto-Escuela, 2010, Dopamine D2 and 5-hydroxytryptamine 5-HT(2A) receptors assemble into functionally interacting heteromers, Biochem Biophys Res Commun, 401, 605, 10.1016/j.bbrc.2010.09.110 · DOI
  9. Burghardt, 2004, The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine, Biol Psychiatry, 55, 1171, 10.1016/j.biopsych.2004.02.029 · DOI · Paper page
  10. Bymaster, 2002, Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex, Psychopharmacology (Berl), 160, 353, 10.1007/s00213-001-0986-x · DOI · Paper page
  11. Chamberlain, 2007, Lack of deleterious effects of buspirone on cognition in healthy male volunteers, JPsychopharmacol, 21, 210, 10.1177/0269881107068066 · DOI
  12. Cilia, 2011, Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis, Mov Disord, 26, 225, 10.1002/mds.23480 · DOI · Paper page
  13. Cools, 2005, Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity, Neuropsychopharmacology, 30, 1362, 10.1038/sj.npp.1300704 · DOI
  14. Costa, 2013, Methylphenidate effects on neural activity during response inhibition in healthy humans, Cereb Cortex, 23, 117989, 10.1093/cercor/bhs107 · DOI
  15. Crean, 2002, Effect of tryptophan depletion on impulsive behavior in men with or without a family history of alcoholism, Behav Brain Res, 136, 349, 10.1016/S0166-4328(02)00132-8 · DOI
  16. Crockett, 2009, Reconciling the role of serotonin in behavioral inhibition and aversion: acute tryptophan depletion abolishes punishment-induced inhibition in humans, J Neurosci, 29, 11993, 10.1523/JNEUROSCI.2513-09.2009 · DOI · Paper page
  17. Cubillo, 2012, Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys, Cereb Cortex, 24, 174, 10.1093/cercor/bhs296 · DOI · Paper page
  18. Drueke, 2010, Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers, Hum Psychopharmacol, 25, 472, 10.1002/hup.1141 · DOI · Paper page
  19. Eagle, 2009, Serotonin depletion impairs waiting but not stop-signal reaction time in rats: implications for theories of the role of 5-HT in behavioral inhibition, Neuropsychopharmacology, 34, 1311, 10.1038/npp.2008.202 · DOI
  20. Fletcher, 2007, Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test, Psychopharmacology (Berl), 195, 223, 10.1007/s00213-007-0891-z · DOI · Paper page
  21. Goldstein, 2011, Catechols in post-mortem brain of patients with Parkinson disease, Eur J Neurol, 18, 703, 10.1111/j.1468-1331.2010.03246.x · DOI
  22. Harmer, 2013, ‘It's the way that you look at it’–a cognitive neuropsychological account of SSRI action in depression, Philos Trans R Soc B Biol, 368, 20120407, 10.1098/rstb.2012.0407 · DOI · Paper page
  23. Harrison, 1999, Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination, Behav Brain Res, 100, 99, 10.1016/S0166-4328(98)00117-X · DOI
  24. Haugbøl, 2007, Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome, Int J Neuropsychopharmacol, 10, 245, 10.1017/S1461145706006559 · DOI · Paper page
  25. Homberg, 2007, Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility, Eur J Neurosci, 26, 2066, 10.1111/j.1460-9568.2007.05839.x · DOI · Paper page
  26. Hughes, 2010, Parkinson's disease and healthy aging: independent and interacting effects on action selection, Hum Brain Mapp, 31, 1886, 10.1002/hbm.20979 · DOI · Paper page
  27. Humpston, 2013, Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task, J Psychopharmacol, 27, 213, 10.1177/0269881112466182 · DOI
  28. Khullar, 2011, Wavelet-based fMRI analysis: 3-D denoising, signal separation, and validation metrics, Neuroimage, 54, 2867, 10.1016/j.neuroimage.2010.10.063 · DOI
  29. Kirby, 2011, Contributions of serotonin in addiction vulnerability, Neuropharmacology, 61, 421, 10.1016/j.neuropharm.2011.03.022 · DOI · Paper page
  30. LeMarquand, 1999, Behavioral disinhibition induced by tryptophan depletion in nonalcoholic young men with multigenerational family histories of paternal alcoholism, Am J Psych, 156, 1771, 10.1176/ajp.156.11.1771 · DOI · Paper page
  31. Lewis, 2003, Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry, JNeurosci, 23, 6351, 10.1523/JNEUROSCI.23-15-06351.2003 · DOI · Paper page
  32. Macoveanu, 2013, Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition, Neuropsychopharmacology, 38, 996, 10.1038/npp.2012.264 · DOI · Paper page
  33. Mendelsohn, 2009, Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review, Neurosci Biobehav Rev, 33, 926, 10.1016/j.neubiorev.2009.03.006 · DOI · Paper page
  34. Miyazaki, 2011, Activation of the central serotonergic system in response to delayed but not omitted rewards, Eur J Neurosci, 33, 153, 10.1111/j.1460-9568.2010.07480.x · DOI · Paper page
  35. Moret, 1996, Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain, Eur J Pharmacol, 295, 189, 10.1016/0014-2999(95)00646-X · DOI
  36. Nandam, 2011, Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability, Biol Psychiatry, 69, 902, 10.1016/j.biopsych.2010.11.014 · DOI
  37. Nombela, 2014, Multiple modes of impulsivity in Parkinson's disease, PLoS One, 9, e85747, 10.1371/journal.pone.0085747 · DOI · Paper page
  38. Obeso, 2011, Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease, Exp Brain Res, 212, 371, 10.1007/s00221-011-2736-6 · DOI · Paper page
  39. Ortega, 2012, Regulation of central noradrenergic activity by 5-HT(3) receptors located in the locus coeruleus of the rat, Neuropharmacology, 62, 2472, 10.1016/j.neuropharm.2012.02.018 · DOI
  40. Peelle, 2010, Evaluating an acoustically quiet EPI sequence for use in fMRI studies of speech and auditory processing, Neuroimage, 52, 1410, 10.1016/j.neuroimage.2010.05.015 · DOI
  41. Politis, 2010, Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study, Neurobiol Dis, 40, 216, 10.1016/j.nbd.2010.05.028 · DOI · Paper page
  42. Politis, 2012, Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts, Sci Transl Mede, 4, 128ra41
  43. Rae, 2012, White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function, Neuroimage, 62, 1675, 10.1016/j.neuroimage.2012.06.012 · DOI · Paper page
  44. Robinson, 2008, Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task, Neuropsychopharmacology, 33, 2398, 10.1038/sj.npp.1301636 · DOI
  45. Robinson, 2008, Recurrence in major depressive disorder: a neurocognitive perspective, Psychol Med, 38, 315, 10.1017/S0033291707001249 · DOI · Paper page
  46. Rowe, 2008, Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition, Brain, 131, 2094, 10.1093/brain/awn112 · DOI · Paper page
  47. Sangkuhl, 2011, PharmGKB summary: citalopram pharmacokinetics pathway, Pharmacogenet Genomics, 21, 769, 10.1097/FPC.0b013e328346063f · DOI · Paper page
  48. Smith, 2006, Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data, Neuroimage, 31, 1487, 10.1016/j.neuroimage.2006.02.024 · DOI · Paper page
  49. Swick, 2011, Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks, Neuroimage, 56, 1655, 10.1016/j.neuroimage.2011.02.070 · DOI · Paper page
  50. Tomlinson, 2010, Systematic review of Levodopa dose equivalency reporting in Parkinson's disease, Mov Disord, 25, 2649, 10.1002/mds.23429 · DOI · Paper page
  51. Voon, 2011, Impulse control disorders in Parkinson's disease: recent advances, Curr Opin Neurol, 24, 324, 10.1097/WCO.0b013e3283489687 · DOI · Paper page
  52. Voon, 2011, Impulse control disorders in Parkinson disease: a multicenter case—control study, Ann Neurol, 69, 986, 10.1002/ana.22356 · DOI · Paper page
  53. Walker, 2009, Differential contributions of dopamine and serotonin to orbitofrontal cortex function in the marmoset, Cereb Cortex, 19, 889, 10.1093/cercor/bhn136 · DOI · Paper page
  54. Weintraub, 2011, Neurodegeneration across stages of cognitive decline in Parkinson's disease, Arch Neurol, 68, 1562, 10.1001/archneurol.2011.725 · DOI · Paper page
  55. Weintraub, 2010, Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients, Arch Neurol, 67, 589, 10.1001/archneurol.2010.65 · DOI · Paper page
  56. Winstanley, 2005, Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders, Neuropsychopharmacology, 30, 669, 10.1038/sj.npp.1300610 · DOI · Paper page
  57. Zepf, 2008, Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition, Pharmacopsychiatry, 41, 60, 10.1055/s-2007-1004593 · DOI
  58. Zhang, 2012, Selection and inhibition mechanisms for human voluntary action decisions, Neuroimage, 63, 392, 10.1016/j.neuroimage.2012.06.058 · DOI

Cited by

See all 118

Metadata

Authors
Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B.
Venue
Brain
Published
2014-02-27
Volume
137
Issue
4
Pages
1145-1155
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2138881918
Cited by
118
References
30
FWCI
8.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.